These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 12953804)

  • 1. Apoptotic signaling in multiple myeloma: therapeutic implications.
    Chauhan D; Hideshima T; Anderson KC
    Int J Hematol; 2003 Aug; 78(2):114-20. PubMed ID: 12953804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications.
    Chauhan D; Anderson KC
    Apoptosis; 2003 Aug; 8(4):337-43. PubMed ID: 12815276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis in multiple myeloma: therapeutic implications.
    Chauhan D; Anderson KC
    Apoptosis; 2001; 6(1-2):47-55. PubMed ID: 11321040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways.
    Dehghanifard A; Kaviani S; Abroun S; Mehdizadeh M; Saiedi S; Maali A; Ghaffari S; Azad M
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):311-320. PubMed ID: 29606369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel anti-myeloma agents and angiogenesis.
    Anargyrou K; Dimopoulos MA; Sezer O; Terpos E
    Leuk Lymphoma; 2008 Apr; 49(4):677-89. PubMed ID: 18398734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
    Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
    Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
    Kizaki M; Tabayashi T
    J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth factors and antiapoptotic signaling pathways in multiple myeloma.
    van de Donk NW; Lokhorst HM; Bloem AC
    Leukemia; 2005 Dec; 19(12):2177-85. PubMed ID: 16239913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside.
    Bruno B; Giaccone L; Rotta M; Anderson K; Boccadoro M
    Leukemia; 2005 Oct; 19(10):1729-38. PubMed ID: 16094421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
    Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
    Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for multiple myeloma.
    Anderson KC
    Semin Hematol; 2001 Jul; 38(3):286-94. PubMed ID: 11486317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting signaling pathways in multiple myeloma.
    Federica C; Antonio P; Guido T; Mario B
    Curr Pharm Biotechnol; 2006 Dec; 7(6):407-13. PubMed ID: 17168656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a new age in the treatment of multiple myeloma.
    Piazza FA; Gurrieri C; Trentin L; Semenzato G
    Ann Hematol; 2007 Mar; 86(3):159-72. PubMed ID: 17205287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
    Hideshima T; Richardson P; Chauhan D; Palombella VJ; Elliott PJ; Adams J; Anderson KC
    Cancer Res; 2001 Apr; 61(7):3071-6. PubMed ID: 11306489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation.
    Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
    Apoptosis; 2016 Dec; 21(12):1422-1437. PubMed ID: 27734217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor microenvironment: focus on myeloma.
    Dalton WS
    Cancer Treat Rev; 2003 May; 29 Suppl 1():11-9. PubMed ID: 12738239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.
    Ramachandran IR; Condamine T; Lin C; Herlihy SE; Garfall A; Vogl DT; Gabrilovich DI; Nefedova Y
    Cancer Lett; 2016 Feb; 371(1):117-24. PubMed ID: 26639197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the biology and treatment of multiple myeloma.
    Varterasian ML
    Curr Opin Oncol; 1999 Jan; 11(1):3-8. PubMed ID: 9914870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance in multiple myeloma: approaches to circumvention.
    Dalton WS; Jove R
    Semin Oncol; 1999 Oct; 26(5 Suppl 13):23-7. PubMed ID: 10528891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.